Combination Therapy

A pharmaceutical composition which comprises AZD2171, or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a platinum anti-tumour agent, in association with a pharmaceutically acceptable excipient or carrier.

(canceled)

A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a platinum anti-tumour agent.

(canceled)

The method according to claim 27 or claim 28 wherein AZD2171 is in a form of the free base.

The method according to claim 27 or claim 28 wherein the platinum anti-tumour agent is oxaliplatin.

The method according to claim 27 or claim 28 wherein the platinum anti-tumour agent is cisplatin.

The method according to claim 27 or claim 28 any wherein the platinum anti-tumour agent is carboplatin.

25-26. (canceled)

A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of a platinum anti-tumour agent.

A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of a platinum anti-tumour agent and before, after or simultaneously with an effective amount of ionising radiation.